National Commission into the Regulation of AI in Healthcare: Recommendations for a future regulatory framework
Final report of the UK National Commission into the Regulation of AI in Healthcare, established in September 2025 to advise government on a regulatory framework for software and AI-enabled health technologies. Sets out 38 recommendations under three principles (proportionate lifecycle regulation; system-wide responsibility and safe management; trust, transparency and predictability), covering device qualification and classification, risk-proportionate evidence over the lifecycle, general-purpose AI models used inside medical devices, direct-to-consumer products, post-market assurance, adverse-incident sharing, enforcement, and patient transparency.
Publisher
Medicines and Healthcare products Regulatory Agency (MHRA), National Commission into the Regulation of AI in Healthcare
Published
10 Sept 2026
Added
today
DOI
—
Key Findings
- Recommendation 7 proposes an opt-in 'master file' approach for general-purpose platforms, foundation models and underlying technologies used by device manufacturers, and Recommendation 8 asks manufacturers to report product dependencies on underlying general-purpose models; the report names general-purpose models fine-tuned to serve as the basis of a medical device, such as a chatbot, as the case in point.
- Recommendation 11 asks the MHRA to provide guidance on regulatory expectations for direct-to-consumer applications and wearables, including when such a product is a medical device and evidence expectations, recognising that consumers cannot rely on a health professional for risk controls.
- Recommendations 19 and 22 propose a database or tool for sharing information on adverse incidents and enhanced enforcement mechanisms for the MHRA; Recommendation 6 covers predetermined change control plans.
- Recommendations 35, 37 and 38 cover patient transparency about AI in care (with opt-out where possible or appropriate), public communication on safety concerns, and an 'AI sentiment census' run by DHSC and the devolved health departments.
- The report distinguishes lower-risk uses (administrative, general wellbeing, low-risk clinical decision support) from higher-risk uses, and frames the whole healthcare system rather than the regulator alone as responsible for safe deployment.
Methodology Notes
Policy commission chaired by Professor Alastair Denniston with Professor Henrietta Hughes (Patient Safety Commissioner for England) as deputy chair; evidence from a call for evidence, public deliberation, engagement with seldom-heard groups, roundtables and working groups across the four UK nations (the companion 'Research, engagement and call for evidence findings' publication of 11 June 2026 carries the polling). Recommendations document with no primary study data. Full report PDF 119 pages (created 8 September 2026), plus easy-read and Welsh summaries; published on GOV.UK 10 September 2026 under the Open Government Licence.
Topics
Tags
Cite This
APA
Medicines and Healthcare products Regulatory Agency (MHRA), National Commission into the Regulation of AI in Healthcare. (2026). National Commission into the Regulation of AI in Healthcare: Recommendations for a future regulatory framework. https://www.gov.uk/government/publications/national-commission-into-the-regulation-of-ai-in-healthcare-recommendations-for-a-future-regulatory-framework
Related Insights
Digital Mental Health Technology: Device Characterisation, Regulatory Qualification and Classification
Medicines and Healthcare products Regulatory Agency (MHRA) · 3 Feb 2025
Digital Mental Health Technology: Research on identifying and reporting harms associated with the use of DMHT and awareness of the MHRA Yellow Card Scheme
Medicines and Healthcare products Regulatory Agency (MHRA); research by Woodnewton · 20 Nov 2025
Generative AI: Product Safety Standards
Department for Education (UK) · 19 Jan 2026